- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02808416
Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) (PerCellVac3)
May 23, 2022 updated by: Jian Zhang, Guangdong 999 Brain Hospital
Personalized Cellular Vaccine Therapy in Treating Patients With Brain Metastases From Solid Tumors
Cancer patients with brain metastases (BM) have poor prognosis.
Current treatments produce limited efficacy.
Recent advance in cancer immunotherapy has provided important new means to treat cancer patients at advanced stages.
This study is designed to perform a clinical trial to treat advanced caner patients with brain metastases with personalized dendritic cell-based cellular vaccines.
The patients will receive vaccines consisting of mRNA tumor antigen pulsed DCs.
Immune response to the immunized tumor antigens will be monitored.
Safety and efficacy will be observed in this study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open label, single-arm, single-institution, Phase I study designed to investigate the safety and efficacy of personalized cellular tumor vaccines for cancer patients with brain metastases (BM).
BM patients will undergo tumor resection or biopsy and the tumor tissues will be analyzed for the expression of tumor antigens and immune-related genes.
The patients will be immunized with DCs pulsed with mRNA encoded tumor antigens.
Patients will be immunized with DC vaccines on a biweekly basis.
Safety and efficacy will be monitored.
The objective of this study is to assess the safety of the personalized cellular vaccines and to deterimine the antitumor specific T cell responses.
The efficacy of the vaccines will be determined using RANO-BM criteria, progression-free survival and overall survival.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Guangdong 999 Brain Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Solid tumor with brain metastases.
- Patients at the age of 18-65.
- Patients undergo tumor resection or biopsy.
- Patients with Karnofsky scores > or =70
- Patients with normal range of hematologic and metabolic test results.
- Patients must have no corticosteroids treatment at least one week before vaccination.
- Patients capable of understanding the study and signed informed consent.
Exclusion Criteria:
- Infectious diseases HIV, HBV, HCV.
- Documented immunodeficiency.
- Documented autoimmune disease.
- Breast feeding females.
- Pregnant women.
- Any serious or uncontrolled medical or psychiatric conditions, for example, severe pulmonary, cardiac or other systemic disease.
- Patient inability to participate as determined by PI discretion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Personalized cellular vaccine
Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.
|
Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines. Other Names: • Tumor antigen pulsed DC and PBMC, autologous tumor vaccine |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events and severe adverse events (safety and tolerability)
Time Frame: 3 years since the beginning of the first vaccine
|
Incidence of adverse events and severe adverse events to measure safety and tolerability of mRNA-TAA pulsed autologous DC vaccines.
|
3 years since the beginning of the first vaccine
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antitumor specific T cell response
Time Frame: 4 weeks after the last vaccine
|
The frequency of the peripheral CD8+ and CD4+ T cell response to the vaccine will be measured.
|
4 weeks after the last vaccine
|
Progression-free survival
Time Frame: 24 months since the beginning of the first vaccine
|
Progression-free survival will be monitored for 2 year
|
24 months since the beginning of the first vaccine
|
Overall survival
Time Frame: 3 years since the beginning of the first vaccine
|
Overall survival will be monitored for 3 years
|
3 years since the beginning of the first vaccine
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jian Zhang, M.D., Guangdong 999 Brain Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2016
Primary Completion (Actual)
October 31, 2017
Study Completion (Actual)
June 30, 2019
Study Registration Dates
First Submitted
June 17, 2016
First Submitted That Met QC Criteria
June 20, 2016
First Posted (Estimate)
June 21, 2016
Study Record Updates
Last Update Posted (Actual)
May 27, 2022
Last Update Submitted That Met QC Criteria
May 23, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ag-mRNA-Cell-BM-999Brain
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownCancer | Metastatic Cancer | Metastatic Brain CancerChina
-
University of FloridaCompletedBrain Neoplasms | Brain Cancer | Brain Tumors | Seizure | Cancer of the Brain | Cancer of BrainUnited States
-
Eisai Inc.CompletedMetastatic Brain CancerUnited States
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Head and Neck Cancer | Gynecologic Cancer | Brain CancerCanada
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
InSightecActive, not recruitingGlioma | Metastatic Brain CancerCanada
-
Virginia Commonwealth UniversityUnited States Department of DefenseActive, not recruitingBrain Metastases, Adult | Cancer Metastatic to BrainUnited States
-
Institut National de la Santé Et de la Recherche...RecruitingPediatric Cancer | Cancer BrainFrance
Clinical Trials on Personalized cellular vaccine
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...Completed
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...Completed
-
Cell GenesysCompletedMultiple MyelomaUnited States
-
Xuanwu Hospital, BeijingBeijing Neoantigen Biotechnology CompanyRecruitingMalignant Glioma | Recurrent GliomaChina
-
Cell GenesysCompleted
-
Cell GenesysCompleted
-
Anda Biopharmaceutical Development (Shenzhen) Co...Recruiting
-
Changhai HospitalStemirna TherapeuticsUnknownPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Colorectal Adenocarcinoma | Advanced Esophageal Squamous CarcinomaChina